JA Solar Holdings (JASO) Plenty of Order Forms for PERCIUM Solar Cell, BioCryst Pharmaceuticals (BCRX) Upgraded
Online, June 23, 2014 (Newswire.com) - Early this year, JA Solar Holdings Co., Ltd. (JASO) launched the 6x10 PERCIUM cells module in Japanese, British, Israeli, Chinese and German markets and has received positive responses, especially from European and Japanese markets.
According to JASO, since then it has received plenty of enquiries and order forms.
JASO launched mass production of its PERCIUM solar cell on June 20th. The PERCIUM solar cell, the first P-TYPE solar cell in industry that surpasses a conversion efficiency of 20%, has reached an average conversion efficiency of 20.4%.
The 6x10 PERCIUM cells module, which has reached an average power rating of 285W, is expected to be put into mass production one week later. The preparation for mass production has taken only three months since the new product release early this year and the module is expected to reach an average power rating of 290W by the end of the year.
High conversion efficiency and high reliability are two aspects the solar industry highly values as the next step of development. It's also what makes JASO products so outstanding.
To meet the increasing demands of customers, JASO has completed preparations for mass production within a short time and will continue to expand the capacity of PERCIUM solar cells. Currently, JASO has one PERCIUM solar cell production line and will have four this October. JASO expects to have eight in 2015. The capacity of PERCIUM solar cells is expected to reach 170MW by the end of this year and 350MW next year.
JASO is a leading manufacturer of high-performance solar power products that convert sunlight into electricity for residential, commercial, and utility-scale power generation.
More about JA Solar Holdings Co., Ltd. (JASO) at www.jasolar.com
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network (CRWE-PR.com), a social networking service which business model is based on selling advertising to businesses targeting both locally and nationally.
The CRWE-PR Finance ( www.finance.crwe-pr.com ) and the CRWE-Press-Release ( www.crwepressrelease.com ) websites allow Crown Equity Holdings the instant distribution of information to the entire CRWE Network, which has reached the 700th community website in the U.S., associated with 2273 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida, Hattiesburg in Mississippi and 10 provinces in Canada.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded from Market Perform to Outperform with a price target range of $17.00 to $19.00 per share by Wells Fargo.
BCRX designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and rare diseases, with the goal of addressing unmet medical needs of patients and physicians.
More about BioCryst Pharmaceuticals, Inc. (BCRX) at www.biocryst.com
**
CRWE-PR Finance http://finance.crwe-pr.com/2014/06/23/ja-solar-holdings-jaso-plenty-of-order-forms-for-percium-solar-cell-biocryst-pharmaceuticals-bcrx-upgraded/
Read Full Disclaimer at www.finance.crwe-pr.com/disclaimer